A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF ‐β1 and COX ‐2 for Localized Fat Reduction II : Phase I Clinical Trial
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16722 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Mark S Nestor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical and Cosmetic Research, Aventura, Florida, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Abdominoplasty, Transforming Growth Factor beta1, Cyclooxygenase 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sirnaomics Inc.
Abstract (Originalsprache)
Background
Rising demand for non‐invasive body contouring is driven by aesthetics and the obesity epidemic. Deoxycholic acid (DCA) is the only FDA‐approved injectable for fat reduction but can cause side effects and significant local skin reactions (LSR). RNA interference, using small interfering RNA (siRNA) molecules, offers targeted fat reduction by silencing genes involved in fat maintenance. STP705, a siRNA injectable targeting TGF‐β1 and COX‐2, has shown promising preclinical results both in vitro and in animal models.
Aims
To evaluate the safety and tolerability of STP705 for localized fat reduction in subjects undergoing abdominoplasty.
Methods
This phase I dose‐ranging, randomized, vehicle‐controlled trial involved eight females undergoing abdominoplasty who received subcutaneous STP705 injections at varying concentrations and volumes in designated abdominal zones. Safety assessments, including physical exams, lab tests, ECGs, and local skin reactions (LSRs), were conducted at baseline and follow‐ups. Histopathologic evaluations of biopsies collected during abdominoplasty assessed adipocyte apoptosis and tissue remodeling.
Results
STP705 demonstrated a favorable safety profile with no clinically significant changes in lab values, vital signs, or ECGs. Adverse events (AEs) were rare and transient. The incidence, intensity, and duration of LSRs were low throughout the study. Histological analysis revealed adipocyte destruction, fat remodeling, and necrosis.
Conclusion
STP705 was safe and very well‐tolerated and showed preliminary efficacy in inducing adipocyte apoptosis and tissue remodeling, suggesting a safer alternative or adjunct to existing fat reduction therapies. These findings support further trials to establish the safety and efficacy of STP705 for targeted fat reduction and body contouring. Trial Registration ClinicalTrials.gov identifier: NCT05422378
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical and Cosmetic Research, Aventura, Florida, USA.
- Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA.
- Sirnaomics Inc., Gaithersburg, Maryland, USA.
ORCID-Profile: Mark S Nestor
Förderung
- Sirnaomics Inc
Zitieren
APA
Nestor, M. S., Hetzel, J., Awad, N., Bhupalam, V., Lu, P., & Molyneaux, M. (2025). A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF ‐β1 and COX ‐2 for Localized Fat Reduction II : Phase I Clinical Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16722
Vancouver
Nestor MS, Hetzel J, Awad N, Bhupalam V, Lu P, Molyneaux M. A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF ‐β1 and COX ‐2 for Localized Fat Reduction II : Phase I Clinical Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16722
BibTeX
@article{Nestor2025,
author = {Nestor, Mark S and Hetzel, John and Awad, Nardin and Bhupalam, Vishnu and Lu, Patrick and Molyneaux, Michael},
title = {A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF ‐β1 and COX ‐2 for Localized Fat Reduction II : Phase I Clinical Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16722}
}
EUVIMED